Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert


Search Title by author or title

Results of selective laser trabeculoplasty treatment for patients with open-angle glaucoma during a 2 year period

Poster Details

First Author: M.Ponte-Davila PERU

Co Author(s):    J. Izquierdo Villavicencio   F. Quezada Baltodano   I. Ramirez Jimenez   A. Gonz�Ã�¡lez M�Ã�©ndez   B. Rubio Lastra        

Abstract Details


To describe the results of selective laser trabeculoplasty for patients with open-angle glaucoma during a 2-year period.


Research Department, Oftalmosalud Eye Institute, Lima-Peru, Av. Javier Prado Este 1142, San Isidro, Lima, Peru


A descriptive, retrospective, and longitudinal study was conducted among 40 eyes of 20 patients who underwent selective laser trabeculoplasty from 2012 to 2015 and received topical antiglaucoma medication. The following variables were measured: uncorrected visual acuity, best-corrected visual acuity, and intraocular pressure and drugs before treatment and during monitoring controls after 1 day, 7 days, 1 month, 3 months, 6 months, 12 months, and 24 months.


No significant differences were identified between uncorrected visual acuity preoperatively and at 1 year (p=0.091) or between preoperative uncorrected visual acuity preoperatively and at 2 years (p=0.827). Best-corrected visual acuity preoperatively and at 1 year showed no statistical significance (p=0.125); however, best-corrected visual acuity preoperatively and at 2 years had statistical significance (p=0.007). Mean �Â�± standard deviation of preoperative intraocular pressure at 2 years had decreased from 17.28�Â�±5.7 to 13.05�Â�±2.4 mm Hg (statistically significant; p=0.00) and the success rate was 75%. Although the mean �Â�± standard deviation of preoperative for drug use at 2 years decreased from 1.90�Â�±1.1 to 1.65�Â�±1.3, no significant difference (p=0.058) was identified. No complications were identified.


Selective laser trabeculoplasty is an effective and safe treatment that reduces intraocular pressure as well as the number of drugs required by patients with open-angle glaucoma.

Financial Disclosure:


Back to Poster listing